- Oral Selinexor as Maintenance Therapy After First-Line Chemotherapy for Advanced or Recurrent Endometrial Cancer2023 | First Faculty of Medicine
- Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma2021 | First Faculty of Medicine
- Peripheral neuropathy symptoms, pain, and functioning in previously treated multiple myeloma patients treated with selinexor, bortezomib, and dexamethasone2021 | Publication without faculty affiliation
- Association of Selinexor Dose Reductions With Clinical Outcomes in the BOSTON Study2023 | First Faculty of Medicine
- Selinexor-Based Triplet Regimens in Patients With Multiple Myeloma Previously Treated With Anti-CD38 Monoclonal Antibodies2023 | First Faculty of Medicine
- Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk2021 | First Faculty of Medicine
- Effect of age and frailty on the efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma2021 | First Faculty of Medicine
- Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial2020 | First Faculty of Medicine
- AML-Related NPM Mutations Drive p53 Delocalization into the Cytoplasm with Possible Impact on p53-Dependent Stress Response2021 | Faculty of Mathematics and Physics
- Multiple myeloma - are we in 2020 able to cure the patient?2020 | First Faculty of Medicine
